Small Molecule Inhibitors Targeting Chikungunya Virus

Nicole Haese, John Powers, Daniel N. Streblow

Research output: Chapter in Book/Report/Conference proceedingChapter

5 Scopus citations

Abstract

Chikungunya virus (CHIKV) infection in humans is rarely fatal but is often associated with chronic joint and muscle pain. Chronic CHIKV disease is highly debilitating and is associated with viral persistence. To date, there are no approved vaccines or therapeutics to prevent or treat CHIKV infections once they are established. Current palliative treatments aim to reduce joint inflammation and pain associated with acute and chronic CHIKV disease. Development of novel therapeutics that reduces viral loads should positively impact virus inflammatory disease and improve patient outcomes following CHIKV infection. Therapies that target multiple aspects of CHIKV replication cycle should be developed since the virus is capable of rapidly mutating around any single therapeutic. This review summarizes the current status of small molecule inhibitor development against CHIKV.

Original languageEnglish (US)
Title of host publicationCurrent Topics in Microbiology and Immunology
PublisherSpringer Science and Business Media Deutschland GmbH
Pages107-139
Number of pages33
DOIs
StatePublished - 2022

Publication series

NameCurrent Topics in Microbiology and Immunology
Volume435
ISSN (Print)0070-217X
ISSN (Electronic)2196-9965

ASJC Scopus subject areas

  • Immunology and Allergy
  • Microbiology
  • Immunology
  • Microbiology (medical)

Fingerprint

Dive into the research topics of 'Small Molecule Inhibitors Targeting Chikungunya Virus'. Together they form a unique fingerprint.

Cite this